Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1413, 2003-01, pp. : 5-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Less toxicity with pemetrexed spells savings in NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 438, 2003-01 ,pp. :
Access to resources
Recommend
PCV13 spells cost savings in several settings
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :
Pemetrexed beneficial in NSCLC, but only for certain types
Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. :
Gemcitabine plus pemetrexed promising in advanced NSCLC
Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. :
Maintenance pemetrexed too costly for NSCLC in China
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 671, 2013-01 ,pp. :